NasdaqGS - Delayed Quote USD
Nuvalent, Inc. (NUVL)
94.93
+2.20
+(2.37%)
At close: November 22 at 4:00 PM EST
94.93
0.00
(0.00%)
After hours: November 22 at 4:02 PM EST
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 6 | 11 | 11 |
| Avg. Estimate | -1.05 | -1.01 | -3.72 | -4.41 |
| Low Estimate | -1.33 | -1.22 | -4.22 | -5.51 |
| High Estimate | -0.7 | -0.88 | -3.03 | -3.28 |
| Year Ago EPS | -0.62 | -0.69 | -2.17 | -3.72 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 5 | 10 | 10 |
| Avg. Estimate | -- | -- | -- | 7.5M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 75M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.58 | -0.64 | -0.74 | -0.89 |
| EPS Actual | -0.62 | -0.69 | -0.88 | -1.28 |
| Difference | -0.04 | -0.05 | -0.14 | -0.39 |
| Surprise % | -6.05% | -7.37% | -19.21% | -44.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.05 | -1.01 | -3.72 | -4.41 |
| 7 Days Ago | -0.95 | -0.9 | -3.75 | -4.1 |
| 30 Days Ago | -0.96 | -0.91 | -3.37 | -4.21 |
| 60 Days Ago | -0.97 | -0.93 | -3.38 | -4.22 |
| 90 Days Ago | -0.96 | -0.89 | -3.35 | -4.08 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | 1 | -- | 3 |
| Up Last 30 Days | 3 | 1 | -- | 3 |
| Down Last 7 Days | 5 | 3 | 8 | 5 |
| Down Last 30 Days | 4 | 2 | 7 | 4 |
Growth Estimates
| CURRENCY IN USD | NUVL | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -68.59% | -- | -- | 5.00% |
| Next Qtr. | -46.16% | -- | -- | 12.00% |
| Current Year | -71.20% | -- | -- | 2.10% |
| Next Year | -18.64% | -- | -- | 12.20% |
Upgrades & Downgrades
| Maintains | BMO Capital: Outperform to Outperform | 11/13/2024 |
| Initiated | UBS: Neutral | 10/24/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 10/4/2024 |
| Maintains | Guggenheim: Buy to Buy | 9/16/2024 |
| Maintains | Wedbush: Outperform to Outperform | 9/16/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 9/16/2024 |
Related Tickers
PCVX Vaxcyte, Inc.
88.54
+0.17%
CRNX Crinetics Pharmaceuticals, Inc.
56.06
-1.70%
RVMD Revolution Medicines, Inc.
56.75
-0.05%
ACLX Arcellx, Inc.
90.44
+3.69%
MLTX MoonLake Immunotherapeutics
54.32
+4.74%
BPMC Blueprint Medicines Corporation
94.15
-2.56%
ELVN Enliven Therapeutics, Inc.
24.54
-3.42%
DNTH Dianthus Therapeutics, Inc.
22.34
+10.21%
NRIX Nurix Therapeutics, Inc.
22.05
-1.43%
KRYS Krystal Biotech, Inc.
190.40
+4.45%